A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Cell Therapy CDMO Market Is Going to Boom |• Lonza • WuXi AppTec - openPR.com
Cell Therapy CDMO Market Is Going to Boom |• Lonza • WuXi AppTec - openPR.com
Lonza Group AG stock: quiet consolidation or coiled spring for 2026? - AD HOC NEWS
Lonza Group AG stock: quiet consolidation or coiled spring for 2026? - AD HOC NEWS
Lonza Group AG stock: quiet consolidation or coiled spring for 2026? - AD HOC NEWS
Lonza Group AG stock: quiet consolidation or coiled spring for 2026? - AD HOC NEWS
Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Down 28.5% in December - MarketBeat
Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Down 28.5% in December - MarketBeat
Futures Contracts for Lonza Group Futures - TradingView — Track All Markets
Futures Contracts for Lonza Group Futures - TradingView — Track All Markets
Is There Now An Opportunity In Lonza Group AG (VTX:LONN)? - simplywall.st
Is There Now An Opportunity In Lonza Group AG (VTX:LONN)? - simplywall.st
Will Lonza Group AG (Common Stock) (LO3A) stock gain from green policies - Weekly Gains Summary & Technical Confirmation Alerts - Bollywood Helpline
Will Lonza Group AG (Common Stock) (LO3A) stock gain from green policies - Weekly Gains Summary & Technical Confirmation Alerts - Bollywood Helpline
Lonza CHI: Organic capsules for next-gen plant-based nutraceuticals - nutritioninsight.com
Lonza CHI: Organic capsules for next-gen plant-based nutraceuticals - nutritioninsight.com
Lonza Group (OTCMKTS:LZAGY) Sees Unusually-High Trading Volume - What's Next? - MarketBeat
Lonza Group (OTCMKTS:LZAGY) Sees Unusually-High Trading Volume - What's Next? - MarketBeat
Lonza Group, Catalent, and Recipharm Lead the $12.5 Billion Inhaled Drugs Contract Manufacturing Mar - pharmiweb.com
Lonza Group, Catalent, and Recipharm Lead the $12.5 Billion Inhaled Drugs Contract Manufacturing Mar - pharmiweb.com
Lonza Group, Catalent, and Recipharm Lead the $12.5 Billion Inhaled Drugs Contract Manufacturing Market, 2025-2033: Insights by Service, Product, End-Use and Region - ResearchAndMarkets.com - The AI Journal
Lonza Group, Catalent, and Recipharm Lead the $12.5 Billion Inhaled Drugs Contract Manufacturing Market, 2025-2033: Insights by Service, Product, End-Use and Region - R...
Microsize Expands Global Footprint With Bold Move Into European Micronization - MyChesCo
Microsize Expands Global Footprint With Bold Move Into European Micronization - MyChesCo
Lonza’s Growth Hinges On Biologics, But Risks Remain - Finimize
Lonza’s Growth Hinges On Biologics, But Risks Remain - Finimize
How Lonza Group AG (Common Stock) (LO3A) stock behaves under inflation pressure - July 2025 Final Week & Risk Managed Investment Signals - Newser
How Lonza Group AG (Common Stock) (LO3A) stock behaves under inflation pressure - July 2025 Final Week & Risk Managed Investment Signals - Newser
How Lonza Group AG (Common Stock) (LO31) stock trades in high volatility - July 2025 News Drivers & Daily Technical Forecast Reports - Newser
How Lonza Group AG (Common Stock) (LO31) stock trades in high volatility - July 2025 News Drivers & Daily Technical Forecast Reports - Newser
What MACD trends signal for Lonza Group AG (Common Stock) (LO3A) stock - Trade Volume Summary & Short-Term High Return Ideas - Newser
What MACD trends signal for Lonza Group AG (Common Stock) (LO3A) stock - Trade Volume Summary & Short-Term High Return Ideas - Newser
Morgan Stanley Keeps Their Buy Rating on Lonza Group Ltd (LONN) - The Globe and Mail
Morgan Stanley Keeps Their Buy Rating on Lonza Group Ltd (LONN) - The Globe and Mail
Biologics CDMO Market Trends and Investment Forecast to 2033: Features Analysis of Lonza Group, Cata - PharmiWeb.com
Biologics CDMO Market Trends and Investment Forecast to 2033: Features Analysis of Lonza Group, Cata - PharmiWeb.com
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page